Profile data is unavailable for this security.
About the company
VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.
- Revenue in CNY (TTM)1.59bn
- Net income in CNY107.45m
- Incorporated1995
- Employees2.21k
- LocationVcanbio Cell & Gene Engineering Corp LtdNo.45 Dongjiu AvenueAirport Economic AreaTIANJIN 300384ChinaCHN
- Phone+86 2 258617160
- Fax+86 2 258617161
- Websitehttp://www.vcanbio.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Microport EP MedTech Co Ltd | 383.99m | 35.90m | 9.84bn | 577.00 | 274.12 | 5.69 | -- | 25.63 | 0.0763 | 0.0763 | 0.816 | 3.68 | 0.2081 | 1.30 | 7.04 | 665,493.30 | 1.95 | -- | 2.05 | -- | 57.86 | -- | 9.35 | -- | 13.82 | -- | 0.0109 | -- | 26.46 | -- | 85.17 | -- | -- | -- |
| Vcanbio Cell & Gene Engineering Corp Ltd | 1.59bn | 107.45m | 10.16bn | 2.21k | 92.23 | 2.81 | -- | 6.38 | 0.2354 | 0.2354 | 3.45 | 7.73 | 0.2977 | 1.90 | 2.59 | 721,260.30 | 1.90 | 1.13 | 2.68 | 1.61 | 68.10 | 67.76 | 6.38 | 3.84 | 1.48 | 7.89 | 0.0296 | 0.00 | 2.24 | 3.78 | -5.78 | 12.43 | -7.11 | -- |
| Shenzhen YHLO Biotech Co Ltd | 1.90bn | 288.64m | 10.58bn | 1.76k | 36.93 | 3.98 | -- | 5.56 | 0.5026 | 0.5026 | 3.32 | 4.66 | 0.4842 | 1.07 | 4.58 | 1,081,307.00 | 5.85 | 16.43 | 7.46 | 24.16 | 63.98 | 53.26 | 12.08 | 20.01 | 1.28 | 9.13 | 0.2474 | 30.28 | -48.42 | 23.02 | -64.93 | 56.32 | 28.88 | -- |
| Shinva Medical Instrument Co Ltd | 10.12bn | 692.34m | 10.92bn | 8.21k | 12.74 | 1.46 | -- | 1.08 | 1.41 | 1.41 | 18.31 | 12.34 | 0.6775 | 2.20 | 4.96 | 1,232,589.00 | 4.72 | 4.63 | 9.14 | 10.76 | 25.62 | 24.22 | 6.96 | 6.12 | 0.8303 | -- | 0.1637 | 15.91 | 7.87 | -0.5342 | 30.78 | 95.70 | -5.90 | 61.86 |
| Qingdao Haier Biomedical Co Ltd | 2.24bn | 358.01m | 11.35bn | 2.64k | 31.66 | 2.64 | -- | 5.07 | 1.13 | 1.13 | 7.04 | 13.53 | 0.4018 | 5.12 | 6.38 | 848,473.70 | 6.56 | 11.49 | 8.29 | 15.22 | 47.82 | 49.98 | 16.34 | 25.20 | 2.53 | -- | 0.0316 | 26.53 | -20.36 | 22.07 | -32.41 | 28.94 | 20.64 | -- |
| Shandong Weigao Orthopaedic Devce Co Ltd | 1.28bn | 154.60m | 11.78bn | 2.21k | 76.31 | 3.01 | -- | 9.17 | 0.3858 | 0.3858 | 3.20 | 9.78 | 0.2524 | 0.6714 | 4.03 | 581,131.60 | 3.14 | 10.97 | 3.95 | 13.69 | 62.40 | 77.33 | 12.43 | 27.08 | 3.62 | -- | 0.0096 | 17.90 | -30.55 | 1.17 | -79.36 | -19.11 | -4.31 | -- |
| Beijing Wandong Medical Technolgy Co Ltd | 1.40bn | 184.09m | 12.02bn | 1.06k | 65.23 | 2.54 | -- | 8.56 | 0.262 | 0.262 | 2.00 | 6.74 | 0.2647 | 2.76 | 4.01 | 1,325,746.00 | 3.50 | 5.30 | 3.91 | 6.21 | 38.83 | 45.21 | 13.22 | 16.46 | 9.48 | -- | 0.0179 | 35.82 | 10.30 | 5.32 | 7.51 | 4.22 | -16.66 | 5.39 |
Data as of Sep 13 2024. Currency figures normalised to Vcanbio Cell & Gene Engineering Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 1.77m | 0.38% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 1.54m | 0.33% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.32m | 0.28% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 1.10m | 0.24% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 995.90k | 0.21% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 861.30k | 0.18% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 668.50k | 0.14% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2024 | 444.58k | 0.10% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 425.90k | 0.09% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 413.20k | 0.09% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
